Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other solid neoplasm 3

Conditions

Breast Neoplasms 17Solid Tumor 3Thrombocytosis 1Prostatic Neoplasms 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1Leukemia, Myeloid, Acute 1Leukemia, Myeloid, Accelerated Phase 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hodgkin Disease 1Hematologic Neoplasms 1Endometrial Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms, Male 1Brain Neoplasms 1Blast Crisis 1Anemia 1

Interventions

pembrolizumab 10Docetaxel 8senaparib 7Injections 7Capecitabine 7Paclitaxel 6Cisplatin 6Irinotecan 5Fluorouracil 5Leucovorin 4Cyclophosphamide 4Bevacizumab 4tislelizumab 3pertuzumab 3fludarabine 3atezolizumab 3Rifampin 3Oxaliplatin 3Itraconazole 3Gemcitabine 3ontuxizumab 2navoximod 2fluzoparib 2durvalumab 2Trastuzumab 2Nivolumab 2Midazolam 2Hydroxychloroquine 2Carboplatin 2130-nm albumin-bound paclitaxel 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Solid Tumor × pertuzumab × Clear all
NCT02593708 2017-11-17

Phase1 of Neratinib+Trastuzumab, Pertuzumab, Paclitaxel in Patients With Advanced Solid Tumors/HER2+

University of California, San Francisco

Phase 1 Terminated
6 enrolled
Other solid neoplasm

Solid Tumor

NCT02490475 2017-05-17

A Multiple-Dose Study of RhuMab 2C4 and Docetaxel in the Treatment of Advanced Solid Tumors

Hoffmann-La Roche

Phase 1 Completed
19 enrolled 25 charts
Other solid neoplasm

Solid Tumor

NCT02494596 2015-11-10

A Phase Ib, Open-label, Multicenter Study of the Safety and PK of the Combination of rhuMAb2c4 (Omnitarg), a Recombinant Humanized Antibody to HER2, and Capecitabine (Xeloda) in Patients With Advanced Solid Tumors

Hoffmann-La Roche

Phase 1 Completed
19 enrolled 16 charts
Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡